期刊文献+

卵巢癌抗独特型单链抗体6B11ScFv/鼠HSP70融合蛋白复性条件的研究

Refolding of the ovarian anti-idiotypic single chain antibody 6B11ScFv and mouse HSP70 fusion protein expressed by E.coli
下载PDF
导出
摘要 目的探讨大肠杆菌表达的卵巢癌抗独特型单链抗体/小鼠热休克蛋白70(6B11ScFv/mHSP70)融合蛋白包涵体变性、复性条件,以确定其最佳体外复性条件。方法大肠杆菌表达大量融合蛋白6B11ScFv/mHSP70:①比较不同的裂解液(8mol/L尿素和6mol/L盐酸胍)对包涵体的裂解效率及其对复性蛋白活性的影响;②探索序贯稀释方法,以及氧化还原环境和复性液中不同浓度L-精氨酸对蛋白稀释复性的影响;③比较稀释复性和柱上复性对融合蛋白复性效率及活性的影响。采用Bradford法测定包涵体裂解液与复性后蛋白浓度。所有复性蛋白活性的检测均采用ELISA方法。结果以包涵体形式表达6B11ScFv/mHSP70蛋白:①经6mol/L盐酸胍裂解包涵体的效率远高于8mol/L尿素,但前者复性所得蛋白活性低,6mol/L盐酸胍彻底裂解的包涵体经8mol/L尿素透析后再复性,复性效率显著提高;②序贯稀释方法可提高蛋白复性效率;加入0.5mol/LL-精氨酸可降低稀释复性过程中蛋白聚集物的产生,提高复性效率;加入还原型谷胱甘肽(GSH)与氧化型谷胱甘肽(GSSH)浓度比为1:5时,可提高复性后蛋白活性;③柱上复性可一步完成蛋白的复性和纯化,所得蛋白纯度较高,但复性效率和复性后蛋白活性较稀释复性低。结论本研究建立了6B11ScFv/mHSP70融合蛋白的最佳复性条件:包涵体经6mol/L盐酸胍彻底裂解后,再经8mol/L尿素透析,然后进行序贯稀释复性,且复性液中加入0.5mol/LL-精氨酸和GSH:GSSH=1:5以提高复性效率和蛋白活性,为进一步研究该蛋白的功能奠定了基础。 Objective To explore and to determined the optima conditions for refolding of the prokaryotic 6B 11ScFv/mHSP70 fusion protein in vitro.Methods To express the recombinant 6B11ScFv/mHSP70 fusion protein by the prokaryotic expression system E.coli: (1) To compare the efficiency of 8 mol/L urea and 6 mol/L guanidine hydrochloride in solution of the inclusion body; (2) To examine the effects of sequential dilution method, presence of different redox system and diverse L-arginine concentration on protein aggregation and activity during the refolding process; (3) To investigate the value of dilution refolding and on-column refolding in the recovery of active 6B 11ScFv/mHSP70 protein. The concentrations of protein in both inclusion body lysate and refolding buffers were determined by Bradford method. We evaluate the activity of this fusion protein to combine with specific antibody by ELISA.Results The recombinant proteins were expressed in the form of inclusion body in E.coli BL21(DE3): (1) The solution efficiency of 6 mol/L guanidine hydrochloride was much higher than that of 8 mol/L urea. But the former protein activity after refolding was poorer than the latter. To dissolve the inclusion body in 6 mol/L guanidine hydrochloride and then dialyze with 8 mol/L urea before the refolding process exhibits excellent efficiency and protein activity; (2) The sequential dilution procedure and the addition of 0.5 mol/L L-arginine could effectively reduce protein aggregation in the dilution process. The addition (GSH:GSSH = 1:5) may facilitate refolding but not suppress aggregation; (3) The on-column refolding could achieve both recovery and purification of the protein in a single procedure but with lower refolding efficiency and poorer activity than dilution refolding for this protein. Conclusions We establish the optimal solution and refolding conditions for the 6B11ScFv/mHSP70 fusion protein. The inclusion body of the fusion protein was dissolved thoroughly in 6 mol/L guanidine hydrochloride, and then dialyzed with 8 mol/L urea. The dissolved extracts were refolding in buffers with 0.5 mol/L L-arginine and GSH:GSSH = 1:5 by sequential dilution. And the refolding protein shows satisfactory immunoactivity and could be used in further research of protein functions.
出处 《中国医药生物技术》 CSCD 2009年第6期424-429,共6页 Chinese Medicinal Biotechnology
基金 国家自然科学基金(30772320)
关键词 卵巢肿瘤 重组融合蛋白质类 HSP70热休克蛋白质类 抗体 包涵体 Ovarian neoplasms Recombinant fusion proteins HSP70 heat-shock proteins Antibodies Inclusion bodies
  • 相关文献

参考文献11

  • 1Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEB J, 1996, 10(1):49-56.
  • 2张果,昌晓红,石菁菁,成夜霞,李巍,叶雪,程洪艳,付天云,魏丽惠,崔恒.卵巢癌抗独特型单链抗体6B11ScFv与鼠HSP70融合蛋白的构建、表达及鉴定[J].中国医药生物技术,2008,3(5):336-342. 被引量:5
  • 3刘春雨,崔恒,昌晓红,叶雪,付天云,程洪艳,张果,熊英,成夜霞,张丽,赵旸.6B11ScFv-mHSP70融合蛋白诱导抗卵巢癌免疫应答的体外实验研究[J].中国妇产科临床杂志,2008,9(4):274-278. 被引量:2
  • 4Singh SM, Panda AK. Solubilization and refolding of bacteria/inclusion body proteins. J Biosci Bioeng, 2005, 99(4):303- 310.
  • 5Bradford MM. A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976, 72:248-254.
  • 6Vallejo LF, Rinas U. Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microb Cell Fact, 2004, 3(2):11.
  • 7Tsumoto K, Ejima D, Kumagai I, et al. Practical considerations in refolding proteins from inclusion bodies. Protein Expr Pudf, 2003, 28(1):1-8.
  • 8West SM, Guise AD, Chaudhuri JB. A comparison of the denaturants urea and guanidine hydrochloride on protein refolding. Food Bioproducts Processing, 1997, 75(1):50-56.
  • 9Ho JG, Middelberg AR Estimating the potential refolding yield of recombinant proteins expressed as inclusion bodies. Biotechnol Bioeng, 2004, 87(5):584-592.
  • 10Wang SSS, Chang CK, Peng MJ, et al. Effect of glutathione redox system on lysozyme refolding in size exclusion chromatography. Food Bioproducts Processing, 2006, 84(1): 18-27.

二级参考文献16

  • 1钱和年,吕文英.ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES AGAINST ANTI-OVARIAN CARCINOMA MONOCLONAL ANTIBODY COC166-9 GENERATION AND APPLICATION[J].Chinese Medical Journal,1994(2):21-25. 被引量:5
  • 2张香云,钱和年,邱并生,崔恒,冯捷,黄华梁,傅天云,李文锦,王建六,周萍,李小平.6B11卵巢癌抗独特型单链抗体表达及序列分析[J].北京医科大学学报,1996,28(4):252-255. 被引量:18
  • 3[2]Guo HF,Feng J,Liu G,et al.Establishment and characterization of a human ovarian sarcomatoid carcinoma cell line BUPH:OVSC.Int J Gynecol Cancer,2005,15:856-865.
  • 4[4]Blom B,Ho S,Antonenko S,et al.Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells.J Exp Med,2000,192:1785-1796.
  • 5崔恒,张香云,钱和年,等.卵巢癌基因工程抗独特型疫苗6B11和3D5的基础研究[J].中国肿瘤生物杂志,1997,(4):214.
  • 6刘蓓,崔恒,尤芳蕾,等.卵巢癌抗独特型单链抗体6B11ScFv/鼠GMCSF融合蛋白(6B11mGM)的构建、表达和特性研究[J].中国肿瘤生物治疗杂志,1999,(79):221-223.
  • 7[10]Multhoff G,Botzler C.Heat-shock proteins and the immune response.Ann N Y Acad Sci,1998,851:86-93.
  • 8[11]Belli F,Testori A,Rivoltini L,et al.Vaccination of metastatic melanoma patients with antologous tumor-derived heat shock protein gp96-peptide complexes:clinical and immunologic findings.J Clin Oncol,2002,20:4169-4180.
  • 9[12]Assikis VJ,Daliani D,Pagliaro L,et al.Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell.Proc Am Soc Clin Oncol,2003,22:386.
  • 10[13]Mazzaferro V,Coppa J,Carrabba MG,et al.Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.Clin Cancer Res,2003,9:3235-3245.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部